Lead removal treatment for diabetic kidney disease
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests a treatment that removes lead from the blood to see if it can help slow down kidney damage in people with type 2 diabetes. It may be an option for those with higher lead levels and early-stage kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and kidney disease (diabetic nephropathy)
- Your blood lead level is 5 µg/dL or higher
- Your kidney disease is at an early stage (stage 3 or less)
- You are 18 years old or older
- You do not have high blood pressure or high cholesterol
- You have no history of autoimmune diseases, cancer, or past lead exposure at work
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication that removes lead from the body can slow the worsening of kidney function in people with type 2 diabetes and kidney disease. It might help if you have higher lead levels in your blood.
This study tests whether taking a lactoferrin supplement can help people with type 2 diabetes and chronic kidney disease (stage 3 or 4) by reducing protein in their urine, which is a sign of kidney damage. It may offer a new way to slow the progression of kidney disease.
This study tests an investigational drug called ALN-ANG3 to see if it can help people with diabetic kidney disease. The drug may reduce kidney damage and slow down the loss of kidney function. If you join, you will get the study drug or a placebo (a dummy shot) and be followed by a study doctor.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial focuses on improving how kidney damage is diagnosed and how treatment is planned for people with type 2 diabetes and kidney disease. It may help by using detailed medical history and (if done) kidney biopsy results to guide care more accurately.
Hear when a new Lead-Burdened Type 2 Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.